Please login to the form below

Not currently logged in


This page shows the latest Kesimpta news and features for those working in and with pharma, biotech and healthcare.

Novartis sees demand returning to pre-COVID-19 levels in Q2 results

Novartis sees demand returning to pre-COVID-19 levels in Q2 results

growth of heart failure drug Entresto (sacubitril and valsartan), monoclonal antibody Cosentyx (secukinumab), gene therapy Zolgensma (onasemnogene abeparvovec), wet AMD therapy Lucentis (ranibizumab) and multiple sclerosis drug Kesimpta (ofatumumab).

Latest news

More from news
Approximately 3 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Reaching patients and HCPs during the pandemic Reaching patients and HCPs during the pandemic

    Self-administered injectables, such as Novo Nordisk’s recently approved therapy for adult growth hormone deficiency (GHD), Sogroya (somapacitan), and Novartis’ much-hyped MS treatment, Kesimpta (ofatumumab), will be tested in

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs


Add my company
Purple Agency

An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....

Latest intelligence

What does HCP engagement look like in a post-Covid world?
HCP engagement has changed as a result of the Covid-19 pandemic, with pharmaceutical companies and agencies having to rapidly adjust to a new way of communicating. Digital channels have become...
Breaking the silence: It’s time to talk about the menopause
Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
Committing time to making meaningful connections - top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma...